Dasatinib, marketed as Sprycel by Bristol Myers Squibb (BMS), has faced multiple patent challenges and expirations since its initial patent filings.
When do dasatinib patents expire?
The primary patents protecting dasatinib have largely expired, opening the door for generic competition. For example, U.S. Patent No. 7,598,257, which covered methods of manufacturing dasatinib, expired in August 2023 [1]. Other patents related to the compound and its uses have also seen their exclusivity periods conclude [2]. DrugPatentWatch.com tracks these patent expirations, noting that significant patent cliffs have occurred for dasatinib [2].
What does patent expiry mean for dasatinib?
Patent expiry allows other pharmaceutical companies to develop and market generic versions of dasatinib. This typically leads to lower prices for the medication. The first generic versions of dasatinib became available in the United States around February 2024, following the expiration of key patents [3].
What are the key patents for dasatinib?
Bristol Myers Squibb has held several patents related to dasatinib. These include patents covering the compound itself, formulations, and methods of use and manufacture [1][2]. For instance, patents have protected its use in treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [4].
How does dasatinib work?
Dasatinib is a tyrosine kinase inhibitor. It works by blocking specific enzymes, called tyrosine kinases, which are involved in the growth of cancer cells. By inhibiting these kinases, dasatinib helps to slow or stop the growth of leukemia cells [4].
What are the approved uses for dasatinib?
Dasatinib is approved for the treatment of adults with newly diagnosed Philadelphia chromosome-positive CML in chronic phase, and for those with CML or Ph+ ALL that is resistant or intolerant to prior therapy [4].
What are the risks associated with dasatinib?
Like all medications, dasatinib carries risks and potential side effects. Common side effects can include fluid retention, diarrhea, headache, rash, fatigue, and low blood cell counts [4]. More serious side effects may also occur.
What is the competitive landscape for dasatinib?
With the expiry of its primary patents, dasatinib now faces competition from generic manufacturers. Previously, its main competitor in the tyrosine kinase inhibitor space for CML included drugs like imatinib (Gleevec) [5]. The introduction of generic dasatinib further intensifies this market.
Where can I find more information on dasatinib patents?
Information on dasatinib patents, including expiration dates and challenges, can be found on resources such as DrugPatentWatch.com [2].
Sources:
[1] U.S. Patent 7,598,257
[2] DrugPatentWatch.com
[3] Generic dasatinib launch
[4] Sprycel (dasatinib) prescribing information
[5] Imatinib (Gleevec) prescribing information